Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended March 31, 2013.
“We are focusing on advancing the clinical development of aldoxorubicin for the treatment of patients with soft tissue sarcoma as well as for various other indications, and expanding our oncology pipeline by combining our novel linker platform technology with additional chemotherapeutic agents,” said Steven A. Kriegsman, CytRx President and CEO.
Help employers find you! Check out all the jobs and post your resume.
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company specializing in oncology, today reported financial results for the three months ended March 31, 2013.
“We are focusing on advancing the clinical development of aldoxorubicin for the treatment of patients with soft tissue sarcoma as well as for various other indications, and expanding our oncology pipeline by combining our novel linker platform technology with additional chemotherapeutic agents,” said Steven A. Kriegsman, CytRx President and CEO.
Help employers find you! Check out all the jobs and post your resume.
